PCN3 Quality-Adjusted Survival in Patients With Wild-Type (WT) KRASs Metastatic Colorectal Cancer (mCRC) Receiving First-Line Therapy With Panitumumab Plus FOLFOX Versus FOLFOX Alone
J. Wang(RTI Health Solutions), Jean‐Yves Douillard(Integrated Oncology (United States)), Beth Sherrill(RTI Health Solutions), J. Zhang(RTI Health Solutions), Zhongyun Zhao(Amgen (United States)), Beth Barber(Amgen (United States)), R. Sidhu(Amgen (United States)), Martin Gallagher(The George Institute for Global Health), S. Braun(Amgen (Switzerland))
Cited by 0
Related Papers
Worldwide access to treatment for end-stage kidney disease: a systematic review
|The Lancet|2015|2.3k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k